MYOPK
Phase 3 Recruiting
276 enrolled
Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone
Phase 3 Recruiting
120 enrolled
Vaginal Cuff Brachytherapy Fractionation Study
Phase 3 Recruiting
258 enrolled
Post-Op Pain Control for Prophylactic Intramedullary Nailing.
Phase 3 Recruiting
60 enrolled
Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
Phase 3 Recruiting
650 enrolled
CIME
Phase 3 Recruiting
132 enrolled
EC-CRT-008
Phase 3 Recruiting
242 enrolled
PAROLA
Phase 3 Recruiting
510 enrolled
ECLECTIC
Phase 3 Recruiting
300 enrolled
Tumor HI
Phase 3 Recruiting
16 enrolled
CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC
Phase 3 Recruiting
452 enrolled
Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy
Phase 3 Recruiting
446 enrolled
Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck Squamous Cell Carcinoma
Phase 3 Recruiting
370 enrolled
STABLE-MATES
Phase 3 Recruiting
272 enrolled
Comparing Brief Behavioral Therapy (BBT-CI) and Healthy Eating Education Learning (HEAL) for Cancer-Related Sleep Problems While Receiving Cancer Treatment
Phase 3 Recruiting
400 enrolled
DEBRA
Phase 3 Recruiting
1,670 enrolled
Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial
Phase 3 Recruiting
80 enrolled
NORMA-2
Phase 3 Recruiting
1,749 enrolled
CHIC-STS01
Phase 3 Recruiting
600 enrolled
FRIENDS-01
Phase 3 Recruiting
88 enrolled
Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer
Phase 3 Recruiting
556 enrolled
Interfant-21
Phase 3 Recruiting
160 enrolled
A Randomized Trial of Five Fraction Partial Breast Irradiation (RAPID2)
Phase 3 Recruiting
910 enrolled
A Study of Intra-operative Imaging in Women With Ovarian Cancer
Phase 3 Recruiting
310 enrolled
METLUNG
Phase 3 Recruiting
312 enrolled
Glutamine Plus L. Reuteri Prevents TKI Therapy-diarrhea in Patients With NSCLC
Phase 3 Recruiting
28 enrolled
Erector Spinae Versus Intercostal Nerve Blocks With Liposomal Bupivacaine for Analgesia in Thoracic Surgery
Phase 3 Recruiting
120 enrolled
IMPACT-AML
Phase 3 Recruiting
339 enrolled
LAP100
Phase 3 Recruiting
356 enrolled
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
Phase 3 Recruiting
486 enrolled
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
Phase 3 Recruiting
226 enrolled
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Phase 3 Recruiting
240 enrolled
Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program
Phase 3 Recruiting
600 enrolled
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study
Phase 3 Recruiting
364 enrolled
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Phase 3 Recruiting
382 enrolled
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Phase 3 Recruiting
1,295 enrolled
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
Phase 3 Recruiting
421 enrolled
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
Phase 3 Recruiting
1,100 enrolled
STRIKE
Phase 3 Recruiting
1,040 enrolled
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Phase 3 Recruiting
1,524 enrolled
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Phase 3 Recruiting
1,260 enrolled
HOPE
Phase 3 Recruiting
228 enrolled
GAIN-BCG
Phase 3 Recruiting
330 enrolled
Adaptive Hypofractionated Radiotherapy for Locally Advanced NSCLC Based on Dynamic Enhanced MRI
Phase 3 Recruiting
490 enrolled
MUSIC-Screen
Phase 3 Recruiting
1,284 enrolled
Reduced-dose vs Standard-dose Irradiation for Low-risk Clinical Target Volume in Nasopharyngeal Carcinoma.
Phase 3 Recruiting
700 enrolled
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
Phase 3 Recruiting
875 enrolled
Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases
Phase 3 Recruiting
220 enrolled
Comparing the Efficacy of Different Durations of Maribavir Treatment Regimens in Allo-HSCT
Phase 3 Recruiting
218 enrolled
Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer
Phase 3 Recruiting
300 enrolled